Seeking Alpha

Sangamo BioSciences buys Ceregene

  • Sangamo BioSciences (SGMO) will acquire privately held Ceregene which specializes in AAV gene therapies.
  • The deal gives SGMO CERE-110, a Phase 2 investigational Alzheimer's drug that contains the gene for nerve growth factor. Results are expected in 2015. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)